Portfolio Images

7 / 25

Chicago, IL - ASCO 2012 Annual Meeting: - -96291/LBA8500^--Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma**A. Hauschild during the Oral: Melanoma session at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Monday June 4, 2012. Over 31,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Todd Buchanan 2012 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org

96291LBA8500Phase III randomized openlabel multicenter trial BREAK3 comparing the BRAF kinase inhibitor dabrafenib GSK2118436 with dacarbazine DTIC in patients with BRAFV600Emutated melanomaA. Hauschild Oral Melanoma session

$\Session Number\, Speakers and Attendees$